Theravance Story

Theravance Inc -- USA Stock  

 9.81  0.00  0.00%

Macroaxis does not monitor all media channels or aggregates social signals for Theravance. But even though we do not provide professional-grade financial sentiment analysis on Theravance Inc, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Theravance. Also please take a look at World Market Map.
Glaxo-Innoviva Triple Combo Inhaler Positive in Phase III
GlaxoSmithKline plc GSK and partner Innoviva, Inc. INVA announced that its once-daily single inhaler triple therapy - Trelegy Ellipta - met primary endpoint in a phase III IMPACT study, showing ... GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing ... - Business Wire Theravance Biopharma Highlights Positive Headline Results from IMPACT Study of ... - Markets Insider

Read More...   

Story Momentum

This story impact on price volatility cannot be determined at this time. Please check this story after some time to allow current data to be analyzed.

Similar stores for Theravance

a day ago at 
Have Experts Now Turned Bearish On Innoviva, Inc. , Party City Holdco ...
Innoviva, Inc. recently ticked higher on weak volume. About 0.87 million contracts were traded on 19-Oct-17 compared to daily average volume of 1.01 million shares.
over a week ago at 
Bark or Bite What is The Street Consensus on Innoviva, Inc.
Innoviva, Inc. currently has an Average Broker Rating of 3.06. This number is based on the 5 sell-side firms polled by Zacks.
over two weeks ago at 
Breakfast Technical Briefing on Application Software Stocks -- FireEye ...
prnewswire News
Under review this morning are the following equities FireEye Inc. , Fortinet Inc. , Innoviva Inc. , and Intuit Inc. . Daily Stock Tracker published free research reports on these stocks today at.

Did you try this?

Run Financial Widgets Now

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Hide  View All  Next  Launch Financial Widgets

Price to Sales

Price to Sales Comparative Analysis
Theravance is currently under evaluation in price to sales category among related companies. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.